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Abstract

Background
The efficacy of postoperative radiotherapy (PORT) for thymic epithelial tumors is still controversial. This study aims to clarify the efficacy of PORT for Masaoka stage II and III thymic carcinoma and thymoma using the Japanese Association for Research on the Thymus (JART) database.
Methods
The JART database registered the records of 2,835 patients collected from 32 Japanese institutions from 1991 to 2010. Thymic carcinoma and thymoma at stage II or III were extracted. Efficacy of PORT on relapse-free survival (RFS) and overall survival (OS) was evaluated using the Kaplan-Meier method and the Cox regression analysis.
Results
A total of 1265 patients were consisted of 155 (12.3%) thymic carcinoma and 1,110 (87.7%) thymoma cases; 895 (70.8%) at stage II and 370 (29.2%) at stage III; 403 (31.9%) cases had PORT. PORT for stage II and III thymic carcinoma was associated with increasing RFS (hazard ratio, 0.48; 95% confidence interval, 0.30-0.78; P=0.003), but not with OS (hazard ratio, 0.94; 95% confidence interval, 0.51-1.75; P=0.536).
PORT for stage II and III thymoma was not associated with RFS or OS (P=0.350).
Subgroup analysis for stage III thymoma showed no factor associated with the efficacy of PORT.
Conclusion
In this study, PORT did not increase RFS or OS for stage II and III thymoma, but increased RFS for stage II and III thymic carcinoma. Masaoka-Koga staging 4 have been widely used for the classification of thymic epithelial tumors. An official uniform classification system, however, has not yet been established 5 . The mainstay treatment for thymic epithelial tumors remains surgical resection 6 . Radiotherapy (RT) has also been applied as a palliative or adjuvant therap 6 because of the radiosensitive nature of the tumors 7 , but the efficacy of postoperative radiotherapy (PORT) for thymic epithelial tumors remains unclear. An optimal chemotherapy regimen has not yet been determined 8, 9 .
The International Thymic Malignancy Interest Group (ITMIG) provided radiation therapy definitions and reporting guidelines for thymic malignancies, but did not comment on the guidelines for PORT 10 , and thus the indication for PORT for thymic epithelial tumors is still left up to the individual judgments of respective institutes.
We undertook this database study to clarify the efficacy of PORT for Masaoka stage II or III thymic carcinoma and thymoma using the Japanese Association for Research on the Thymus (JART) database.
MATERIAL AND METHODS
Data Sources
The JART, established by Akira Masaoka and colleagues in 1982, is a nonprofit research organization that contributes to the development of research on thymic epithelial tumors. A nationwide project to create a database for surgically treated thymic epithelial tumors was conducted by the JART in 2012. The records of 2,835 patients collected from 32 leading Japanese institutions from January 1991 to December 2010 were registered in the JART database. The Masaoka staging system was applied to the classification of thymic epithelial tumors in this database.
Institutional Review Board approval was obtained from each institution.
Patient Selection
Eligibility criteria were as follows: (1) 
Statistical analysis
Age and maximum tumor diameter were summarized using mean ± standard deviation and median (range), whereas the categorical variables were summarized using counts and percentages. For continuous variables, the Wilcoxon rank-sum test was used, and for categorical variables, the chi-square test or Fisher's exact test was applied as appropriate, to compare the patient backgrounds with or without the PORT.
Relapse-free survival (RFS) and overall survival (OS) were calculated from the date of surgery. Time-to-event curves for RFS and OS were estimated by the Kaplan-Meier method, and differences in time-to-event curves with and without PORT were evaluated by the log-rank test. The hazard ratio (HR) and corresponding 95% confidence intervals (CIs) were calculated using the Cox proportional-hazards model controlling for Masaoka staging, histology, and completeness of surgery. All P-values were two-sided and P-values < 0.05 were considered as statistically significant. All statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).
This study was approved by the Kyoto University Graduate School and Faculty of Medicine Ethics Committee (E1904). The study was also approved by each participated institutional review board.
RESULTS
Patient characteristics
The scheme of the study population of the 2,835 patients in the JART database is shown in Figure 1 . 
Overall results
The 5-year RFS proportions of the PORT group (n = 403) and the no PORT group (n = Table 2 ).
Relapse-free survival for stage II and stage III thymoma
The 5-year RFS proportions of the PORT group (n = 196) and the no PORT group (n=615) for stage II thymoma were 93.4% and 92.3% (Fig. 2c) . The 5-year RFS proportions of the PORT group (n=119) and the no PORT group (n = 143) for stage III thymoma was 62.0% and 69.3% (Fig. 2d) .
The RFS HR of PORT as analyzed by Cox regression analysis adjusted for Masaoka stage and residual tumor was 0.98 (95% CI, 0.70-1.37; P = 0.905; Table 2 ).
Subgroup analyses comparing PORT to no PORT for patients with stage III thymoma
No factors were associated with the efficacy of PORT for stage III thymoma cases in the subgroup analyses: i.e., WHO histological type, affected organ, tumor size, presence of MG, and completeness of resection. Any subgroup containing fewer than 50 cases was excluded from these analyses. Each HR and 95% CI by subgroup is shown in Figure 3 as a forest plot.
Overall survival for stage II and III thymic carcinoma and thymoma
The 5-yaer OS proportions of the PORT group (n = 25) and the no PORT group (n=30) for stage II thymic carcinoma were 91.1% and 86.8% (Fig. 4a ). The 5-year OS proportions of the PORT group (n = 55) and the no PORT group (n = 44) for stage III thymic carcinoma were 65.0% and 64.0% (Fig. 4b ).
The 5-year OS proportions of the PORT group (n=199) and the no PORT group (n=637) for stage II thymoma were 96.5% and 96.2% (Fig. 4c) Table 3 ).
DISCUSSION
Although adjuvant RT has traditionally been performed for thymoma, many reports have reconsidered its supposed benefit in recent years [11] [12] [13] . However, retrospective cohort studies of the efficacy of PORT for thymic epithelial tumors have not resulted in a consensus 5, 11, [14] [15] [16] . However, in the Japanese article 18 mentioned above, the data were analyzed without adjusting for covariates. As the results of a comprehensive review showed 14, 27 , PORT seemed to adversely impact recurrence for advanced thymoma. Our analysis before adjusting for covariates (Supplement 2) also showed a similar result. This is because the results of meta-analyses are influenced by any bias in the population if the data are not adjusted for covariates. In contrast, the analysis using the ESTS database 16 adjusted for propensity score showed favorable efficacy of adjuvant therapy for thymic epithelial tumors. However, because these statistically reliable results were for all staged thymic epithelial tumors, it is difficult to identify the group whom adjuvant therapy would benefit the most.
We analyzed the efficacy of PORT using the JART database, which is a Japanese nationwide database, with emphasis on histology and Masaoka staging. 
Study Limitations
Since this is a database study, some limitations are inherent in the retrospective data collection. Follow-up schedules were not standardized, possibly resulting in bias towards null hypotheses. Further, the JART database lacks specific details of radiotherapy treatments and does not include information on any treatments performed after relapse; hence, we could not fully evaluate treatment efficacy after relapse.
In addition, we could not evaluate the influence of postoperative chemotherapy because there were only a few patients who underwent it. A future prospective study whose population receives a consistent type of postoperative therapy for thymic carcinoma is essential.
CONCLUSION
In this database study using the JART database, PORT did not increase relapse-free survival or overall survival for stage II and III thymoma, but did increase relapse-free survival for stage II and III thymic carcinoma. 
